Table of Contents Author Guidelines Submit a Manuscript
The Scientific World Journal
Volume 2012 (2012), Article ID 737585, 6 pages
http://dx.doi.org/10.1100/2012/737585
Research Article

Impact of an Interleukin-1 Receptor Antagonist and Erythropoietin on Experimental Myocardial Ischemia/Reperfusion Injury

1Department of Cardiovascular Surgery, University Medical Center of Schleswig-Holstein, Campus Kiel, Arnold-Heller-Straße 3, Haus 18, 24105 Kiel, Germany
2Department of Pathology, University Medical Center of Schleswig-Holstein, 24105 Kiel, Germany
3Department of Anaesthesiology and Intensive Care Medicine, University Medical Center of Schleswig-Holstein, 24105 Kiel, Germany

Received 13 October 2011; Accepted 27 December 2011

Academic Editors: K. Awano, A. Baldi, and G. Di Giammarco

Copyright © 2012 Christina Grothusen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. J. Bailey, A. S. Berson, H. Handelsman, and M. Hodges, “Utility of current risk stratification tests for predicting major arrhythmic events after myocardial infarction,” Journal of the American College of Cardiology, vol. 38, no. 7, pp. 1902–1911, 2001. View at Publisher · View at Google Scholar · View at Scopus
  2. P. G. McGovern, D. R. Jacobs Jr., E. Shahar et al., “Trends in acute coronary heart disease mortality, morbidity, and medical care from 1985 through 1997: the minnesota heart survey,” Circulation, vol. 104, no. 1, pp. 19–24, 2001. View at Google Scholar · View at Scopus
  3. M. L. Simoons, E. Boersma, A. C. Maas, and J. W. Deckers, “Management of myocardial infarction: the proper priorities,” European Heart Journal, vol. 18, no. 6, pp. 896–899, 1997. View at Google Scholar · View at Scopus
  4. W. Wijns, P. Kolh, N. Danchin et al., “Guidelines on myocardial revascularization: the task force on myocardial revascularization of the european society of cardiology (ESC) and the european association for cardio-thoracic surgery (EACTS),” European Heart Journal, vol. 31, no. 20, pp. 2501–2555, 2010. View at Google Scholar
  5. E. S. Weiss, D. D. Chang, D. L. Joyce, L. U. Nwakanma, and D. D. Yuh, “Optimal timing of coronary artery bypass after acute myocardial infarction: a review of California discharge data,” Journal of Thoracic and Cardiovascular Surgery, vol. 135, no. 3, pp. 503–511, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. D. A. Morrison and J. Sacks, “Balancing benefit against risk in the choice of therapy for coronary artery disease: lesson from prospective, randomized, clinical trials of percutaneous coronary intervention and coronary artery bypass graft surgery,” Minerva Cardioangiologica, vol. 51, no. 5, pp. 585–597, 2003. View at Google Scholar · View at Scopus
  7. D. M. Yellon and D. J. Hausenloy, “Myocardial reperfusion injury,” The New England Journal of Medicine, vol. 357, no. 11, pp. 1121–1135, 2007. View at Publisher · View at Google Scholar
  8. F. Merhi-Soussi, B. R. Kwak, D. Magne et al., “Interleukin-1 plays a major role in vascular inflammation and atherosclerosis in male apolipoprotein E-knockout mice,” Cardiovascular Research, vol. 66, no. 3, pp. 583–593, 2005. View at Publisher · View at Google Scholar · View at Scopus
  9. J. Chamberlain, S. Francis, Z. Brookes et al., “Interleukin-1 regulates multiple atherogenic mechanisms in response to fat feeding,” PLoS One, vol. 4, no. 4, Article ID e5073, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. G. Parti, A. D'Ambrosio, S. Mega et al., “Early Interleukin-1 receptor antagonist elevation in patients with acute myocardial infarction,” Journal of the American College of Cardiology, vol. 43, no. 1, pp. 35–38, 2004. View at Publisher · View at Google Scholar · View at Scopus
  11. G. Patti, S. Mega, V. Pasceri et al., “Interleukin-1 receptor antagonist levels correlate with extent of myocardial loss in patients with acute myocardial infarction,” Clinical Cardiology, vol. 28, no. 4, pp. 193–196, 2005. View at Google Scholar · View at Scopus
  12. F. N. Salloum, V. Chau, A. Varma et al., “Anakinra in experimental acute myocardial infarction-does dosage or duration of treatment matter?” Cardiovascular Drugs and Therapy, vol. 23, no. 2, pp. 129–135, 2009. View at Publisher · View at Google Scholar
  13. W. F. Fearon and D. T. Fearon, “Inflammation and cardiovascular disease role of the interleukin-1 receptor antagonist,” Circulation, vol. 117, no. 20, pp. 2577–2579, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. G. Vogiatzi, A. Briasoulis, D. Tousoulis, N. Papageorgiou, and C. Stefanadis, “Is there a role for erythropoietin in cardiovascular disease?” Expert Opinion on Biological Therapy, vol. 10, no. 2, pp. 251–264, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. P. J. O'Brien, G. W. Dameron, M. L. Beck et al., “Cardiac troponin T is a sensitive, specific biomarker of cardiac injury in laboratory animals,” Laboratory Animal Science, vol. 47, no. 5, pp. 486–495, 1997. View at Google Scholar · View at Scopus
  16. G. J. Garcia-Rivas and G. Torre-Amione, “Abnormal mitochondrial function during ischemia reperfusion provides targets for pharmacological therapy,” Methodist Debakey Cardiovascular Journal, vol. 5, no. 3, pp. 2–7, 2009. View at Google Scholar · View at Scopus
  17. A. Abbate, F. N. Salloum, E. Vecile et al., “Anakinra, a recombinant human interleukin-1 receptor antagonist, inhibits apoptosis in experimental acute myocardial infarction,” Circulation, vol. 117, no. 20, pp. 2670–2683, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. I. Ikonomidis, J. P. Lekakis, M. Nikolaou et al., “Inhibition of interleukin-1 by anakinra improves vascular and left ventricular function in patients with rheumatoid arthritis,” Circulation, vol. 117, no. 20, pp. 2662–2669, 2008. View at Publisher · View at Google Scholar · View at Scopus
  19. M. Sharma, N. K. Ganguly, G. Chaturvedi, S. K. Thingnam, S. Majumdar, and R. K. Suri, “Release of pro-inflammatory mediators during myocardial ischemia/reperfusion in coronary artery bypass graft surgery,” Molecular and Cellular Biochemistry, vol. 247, no. 1-2, pp. 23–30, 2003. View at Publisher · View at Google Scholar · View at Scopus
  20. V. Mastromarino, M. Volpe, M. B. Musumeci, C. Autore, and E. Conti, “Erythropoietin and the heart: facts and perspectives,” Clinical Science, vol. 120, no. 2, pp. 51–63, 2011. View at Publisher · View at Google Scholar · View at Scopus
  21. G. Vogiatzi, A. Briasoulis, D. Tousoulis, N. Papageorgiou, and C. Stefanadis, “Is there a role for erythropoietin in cardiovascular disease?” Expert Opinion on Biological Therapy, vol. 10, no. 2, pp. 251–264, 2010. View at Publisher · View at Google Scholar · View at Scopus
  22. C. Klopsch, D. Furlani, R. Gabel et al., “Intracardiac injection of erythropoietin induces stem cell recruitment and improves cardiac functions in a rat myocardial infarction model,” Journal of Cellular and Molecular Medicine, vol. 13, no. 4, pp. 664–679, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. J. E. Baker, D. Kozik, A. K. Hsu, X. Fu, J. S. Tweddell, and G. J. Gross, “Darbepoetin alfa protects the rat heart against infarction: dose-response, phase of action, and mechanisms,” Journal of Cardiovascular Pharmacology, vol. 49, no. 6, pp. 337–345, 2007. View at Publisher · View at Google Scholar · View at Scopus
  24. I. Ott, S. Schulz, J. Mehilli et al., “Erythropoietin in patients with acute st-segment elevation myocardial infarction undergoing primary: percutaneous coronary intervention a randomized, double-blind trial,” Circulation, vol. 3, no. 5, pp. 408–413, 2010. View at Publisher · View at Google Scholar